Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$36.95 USD

36.95
1,964,098

+0.37 (1.01%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $36.96 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Should You Sell QIAGEN (QGEN) Before Earnings?

by Zacks Equity Research

QIAGEN (QGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    Zacks Equity Research

    Can Molecular Diagnostics Drive Hologic's (HOLX) Q4 Earnings?

    by Zacks Equity Research

    Hologic (HOLX) is expected to deliver solid results in Q4 on the back of the increasing market share and utilization of fully-automated Panther system.

      Zacks Equity Research

      Henry Schein Gains on Strategic Buyouts, Cost Concern a Woe

      by Zacks Equity Research

      Henry Schein (HSIC) continues to grow on dental and animal health business, thanks to merger and acquisition activity. However, rising costs continue to be a burden on the company's bottom line.

        Zacks Equity Research

        NuVasive's (NUVA) PRECICE System Gets Expanded FDA Approval

        by Zacks Equity Research

        NuVasive's (NUVA) latest receipt of expanded FDA 510(k) approval for PRECICE is likely to fortify its hold in the limb reconstruction and trauma market.

          Zacks Equity Research

          Abbott Banks on FDA Approvals and Buyouts, Competition Rife

          by Zacks Equity Research

          The market is upbeat about Abbott's (ABT) latest initiatives.

            Zacks Equity Research

            Bruker (BRKR) at a 52-Week High: What's Driving the Stock?

            by Zacks Equity Research

            The new 52-week high of Bruker (BRKR) came on the back of several new initiatives, the most recent one being the introduction of the new CE-IVD marked Fungiplex Candida fast diagnostic assay.

              Zacks Equity Research

              LabCorp (LH) Strong on Strategic Planning, Competition Rife

              by Zacks Equity Research

              LabCorp (LH) grows on strong diagnostics business amid softness in the Covance drug development business.

                Zacks Equity Research

                Henry Schein Closes Merritt Buyout, Expands in Animal Health

                by Zacks Equity Research

                Henry Schein (HSIC) is consistently trying to expand its Animal Health business.

                  Zacks Equity Research

                  CryoLife to Buy JOTEC, Preliminary Revenue Result Out for Q3

                  by Zacks Equity Research

                  CryoLife (CRY) gained access to the $2-billion global market for stent grafts through JOTEC deal.

                    Zacks Equity Research

                    QIAGEN Banks on Tie-Ups & Product Launches, Competition Rife

                    by Zacks Equity Research

                    The market is upbeat about QIAGEN's (QGEN) partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio.